Cytokinetics (CYTK) Income from Continuing Operations (2010 - 2026)
Cytokinetics (CYTK) posted quarterly Income from Continuing Operations of 185203000.0 for Q1 2026, down 12.06% year-over-year from 210590640.95 in Q1 2025, and down 5.25% quarter-over-quarter from 175961000.0 in Q4 2025.
Powered by 
Analysis
Cytokinetics (CYTK) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Cytokinetics (CYTK) has reported Income from Continuing Operations for 17 consecutive years, with 185203000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 12.06% year-over-year to 185203000.0; the TTM figure through Mar 2026 stood at 672647000.0 (down 10.91% YoY), while the FY2025 annual figure was 917658000.0, up 26.54% from the prior year.
- Income from Continuing Operations fell to 185203000.0 in Q1 2026 per CYTK's latest filing, from 175961000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 13681000.0 in Q2 2022 and bottomed at 188893000.0 in Q3 2025.
- Historically, Income from Continuing Operations has averaged 133899647.06 across 5 years, with a median of 136441000.0 in 2024.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations jumped 86.38% — and 2023, when it sank 843.6%.
- Cytokinetics' Income from Continuing Operations stood at 140889000.0 in 2022, then advanced by 17.26% to 116571000.0 in 2023, then dropped by 27.44% to 148559000.0 in 2024, then slipped by 18.45% to 175961000.0 in 2025, then fell by 5.25% to 185203000.0 in 2026.
- Business Quant data shows CYTK's Income from Continuing Operations at 185203000.0 in Q1 2026, 175961000.0 in Q4 2025, and 188893000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Cytokinetics | 9.63 Bn | 8.46 Bn | 25.89 Mn | -179.17 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -179.17 Mn |
| Mar 31, 2026 | -183.62 Mn |
| Dec 31, 2025 | -192.64 Mn |
| Sep 30, 2025 | -178.11 Mn |
| Jun 30, 2025 | -122.59 Mn |
| Mar 31, 2025 | -155.63 Mn |
| Dec 31, 2024 | -147.98 Mn |
| Sep 30, 2024 | -149.73 Mn |
| Jun 30, 2024 | -142.90 Mn |
| Mar 31, 2024 | -133.34 Mn |
| Dec 31, 2023 | -134.58 Mn |
| Sep 30, 2023 | -129.40 Mn |
| Jun 30, 2023 | -129.09 Mn |
| Mar 31, 2023 | -131.43 Mn |
| Dec 31, 2022 | -134.09 Mn |
| Sep 30, 2022 | -115.25 Mn |
| Jun 30, 2022 | -13.68 Mn |
| Mar 31, 2022 | -84.42 Mn |
| Dec 31, 2021 | -25.92 Mn |
| Sep 30, 2021 | -73.36 Mn |